Active-ingredient Dossier
"fluticasone Propionate"]
Active-ingredient Dossier for "fluticasone Propionate"] (inhaled corticosteroid). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: BEXIMCO
- Brand: NOSTRA
- Therapeutic area: Respiratory
What is
Fluticasone Propionate Fluticasone Propionate is an inhaled corticosteroid.
Australian brands containing
Fluticasone Propionate — FLIXOTIDE — SALFLUMIX EASYHALER — FLUTIFORM — AXOTIDE — DYLASTINE — DYMISTA — SERETIDE — EVOCAIR MDI — FLUTICASONE — Fluticasone+Salmeterol Cipla — MISTY-DUO — PAVTIDE
Therapeutic areas
Fluticasone Propionate is registered in respiratory therapeutics with 21 brands and in ophthalmology with 3 brands.
Sponsor landscape
The ingredient is marketed by 11 sponsors, including GlaxoSmithKline, Cipla, Arrotex Pharmaceuticals, Teva Pharma, Viatris and Alphapharm.
PBS and regulatory activity
One brand containing Fluticasone Propionate has PBS-listed items, with the latest PBS schedule date of 1 May 2026. Government expenditure for the ingredient in the 2022–23 fiscal year was approximately $69.7 million across 1.9 million scripts. The latest PBAC outcome was recorded on 1 November 2023, with 4 brands having PBAC outcomes on record. The latest AusPAR was published on 16 December 2013, with 3 brands having AusPARs on record.